SCHEMBL25758337

SCHEMBL25758337

O=[N+]([O-])c1ccc(S(=O)(=O)CCCCN2CCC(Cc3ccccc3)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.58
SLC6A4 P31645 2/20 0.58
SIGMAR1 Q99720 2/20 0.57
CCR3 P51677 1/20 0.57
SLC6A3 Q01959 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
HTT P42858 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
KCNH2 Q12809 1/20 0.52
DRD4 P21917 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIN2B Q13224 1/20 0.52
KDM1A O60341 1/20 0.51
HRH3 Q9Y5N1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758336 0.85 MEN1 (0.62) SLC6A2SLC6A4SIGMAR1CCR3MEN1
SCHEMBL29022584 0.83 SMN1; SMN2 (0.57) SLC6A2SLC6A4CCR3SLC6A3MEN1
SCHEMBL4632909 0.82 MEN1 (0.65) SLC6A2SLC6A4SIGMAR1SLC6A3MEN1
SCHEMBL17628468 0.79 KMT2A (0.70) MEN1KMT2AHTTLMNAMAPT
SCHEMBL7408986 0.78 TMEM97 (0.73) SLC6A2SLC6A4SIGMAR1SLC6A3MEN1
SCHEMBL3156396 0.78 MEN1 (0.77) SIGMAR1CCR3MEN1KMT2AHTT
SCHEMBL5505080 0.77 GRIN2B (0.59) SIGMAR1CCR3GRIN2AGRIN2B
Bromide SCHEMBL7405192 0.77 TMEM97 (0.72) SLC6A2SLC6A4SIGMAR1SLC6A3MEN1
SCHEMBL24070127 0.77 SLC6A2 (0.56) SLC6A2SLC6A4CCR3SLC6A3MEN1
SCHEMBL7397301 0.76 TMEM97 (0.73) SLC6A2SLC6A4SIGMAR1SLC6A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 SLC6A2 1/4885SLC6A4 3/4885SIGMAR1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.